Course InformationTherapautic Area: Pulmonolgy
Credit(s): 1.00 AMA PRA Category 1 Credit(s)™
Activity Dates: October 12, 2017 to October 11, 2018
The content for this activity is derived from the live satellite symposium at the Eastern Pulmonary Conference Annual Meeting titled, “The Role of Novel Combination Therapeutics for the Management of Patients with COPD” in Palm Beach, Florida. The expert faculty will discuss the emerging science of chronic obstructive pulmonary disease (COPD), including combination therapies and the role they have on various types of disease severity. An analysis of clinical trial data for current and emerging combination therapeutics for the treatment of COPD will be reviewed. The faculty will discuss how to implement patient education and shared-decision making into individualized treatment plans to increase the overall quality of life for patients with COPD. Upon completing this activity, physicians will gain further knowledge on how to treat patients with COPD.
Pulmonologists, primary care physicians, and other healthcare clinicians responsible for the care of patients with COPD.
- Discuss the emerging science of COPD, including combination therapies and the role they have on various types of disease severity.
- Analyze clinical trial data for current and emerging combination therapeutics for the treatment of COPD.
- Implement patient education and shared-decision making into individualized treatment plans to increase the overall quality of life for patients with COPD.
Reynold A. Panettieri, MD
Professor of Medicine
Rutgers University School of Medicine
New Brunswick, New Jersey
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|William M. Carrao, MD||Consultant/Advisor: GlaxoSmithKline plc.Speaker’s Bureau: Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline plc.|
|Reynold A. Panettieri, MD||Consultant/Advisor: Amgen Inc.; AstraZeneca; Bristol-Myers Squibb Company; MedImmune; Novartis Pharmaceuticals Corporation; OncoArendi Therapeutics; Research Institute for Fragrance Materials; Theratrophix, LLC; Vertex Pharmaceuticals IncorporatedGrant/Research Support: Amgen Inc.; AstraZeneca; Bristol-Myers Squibb Company; Novartis Pharmaceuticals Corporation; OncoArendi Therapeutics; Theratrophix, LLC; Vertex Pharmaceuticals Incorporated
Speaker’s Bureau: AstraZeneca; MedImmune; Novartis Pharmaceuticals Corporation; Research Institute for Fragrance Materials; Teva Pharmaceutical Industries Ltd.
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Emma Boring and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.Planners, Managers, Reviewers
AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
AcademicCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by independent educational grants from Sunovion Pharmaceuticals Inc. and Boehringer Ingelheim Pharmaceuticals, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Biogen do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact email@example.com.